

## CORRECTION

## Correction: Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis

The PLOS ONE Staff

There are errors in the author affiliations. The correct affiliations are as follows:

Torsten Diesinger<sup>1, 2, 3\*</sup>, Vyacheslav Buko<sup>4,5</sup>, Alfred Lautwein<sup>1</sup>, Radovan Dvorsky<sup>6,7</sup>, Elena Belonovskaya<sup>4</sup>, Oksana Lukivskaya<sup>4</sup>, Elena Naruta<sup>4</sup>, Siarhei Kirko<sup>4</sup>, Viktor Andreev<sup>8</sup>, Dominik Buckert<sup>1,9</sup>, Sebastian Bergler<sup>1</sup>, Christian Renz<sup>1</sup>, Edith Schneider<sup>10</sup>, Florian Kuchenbauer<sup>10,11</sup>, Mukesh Kumar<sup>12</sup>, Cagatay Günes<sup>12</sup>, Berthold Büchele<sup>13</sup>, Thomas Simmet<sup>13</sup>, Dieter Müller-Enoch<sup>1</sup>, Thomas Wirth<sup>1</sup>, Thomas Haehner<sup>1</sup>

**1** Institute of Physiological Chemistry, Ulm University, Ulm, Germany, **2** Department of Internal Medicine, Neu-Ulm Hospital, Neu-Ulm, Germany, **3** Chair of Biochemistry and Molecular Medicine, Witten/Herdecke University, Witten, Germany, **4** Division of Biochemical Pharmacology, Institute of Biochemistry of Biologically Active Substances, Grodno, Belarus, **5** Department of Biotechnology, University of Medical Sciences, Bialystok, Poland, **6** Institute of Biochemistry and Molecular Biology II, Medizinische Fakultät der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany, **7** Max Planck Institute of Molecular Physiology, Dortmund, Germany, **8** Department of Medical Biology and Genetics, Grodno State Medical University, Grodno, Belarus, **9** Department of Internal Medicine II, University Hospital Ulm, Ulm, Germany, **10** Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany, **11** University of British Columbia, Terry Fox Laboratory, Vancouver, Canada, **12** Department of Urology, University Hospital Ulm, Ulm, Germany, **13** Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Ulm, Germany

The publisher apologizes for the error.

## Reference

1. Diesinger T, Buko V, Lautwein A, Dvorsky R, Belonovskaya E, Lukivskaya O, et al. (2020) Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis. PLoS ONE 15(7): e0235990. <https://doi.org/10.1371/journal.pone.0235990> PMID: 32701948



## OPEN ACCESS

**Citation:** The PLOS ONE Staff (2021) Correction: Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis. PLoS ONE 16(2): e0247690. <https://doi.org/10.1371/journal.pone.0247690>

**Published:** February 19, 2021

**Copyright:** © 2021 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.